Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD Science Committee Report 2019. Eur Respir J. 2019. https://doi.org/10.1183/13993003.00164-2019.
Article
PubMed
PubMed Central
Google Scholar
Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD001288.pub4.
Article
PubMed
PubMed Central
Google Scholar
Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340(25):1941–7.
Article
CAS
Google Scholar
Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 2002;16(1):61–71.
Article
CAS
Google Scholar
Agusti C, Rano A, Filella X, Gonzalez J, Moreno A, Xaubet A, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003;123(2):488–98.
Article
CAS
Google Scholar
Sivapalan P, Ingebrigtsen TS, Rasmussen DB, Sorensen R, Rasmussen CM, Jensen CB, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019;6(1):e000407.
Article
Google Scholar
Borresen SW, Klose M, Baslund B, Rasmussen AK, Hilsted L, Friis-Hansen L, et al. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. Eur J Endocrinol. 2017;177(4):287–95.
Article
CAS
Google Scholar
Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. Nat Rev Immunol. 2017;17(4):233–47.
Article
CAS
Google Scholar
Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
Article
Google Scholar
Smit J, Kaasch AJ, Sogaard M, Thomsen RW, Nielsen H, Froslev T, et al. Use of glucocorticoids and risk of community-acquired Staphylococcus aureus Bacteremia: a population-based case-control study. Mayo Clin Proc. 2016;91(7):873–80.
Article
CAS
Google Scholar
Upadhyay J, Trivedi N, Lal A. Risk of future type 2 diabetes mellitus in patients developing steroid-induced hyperglycemia during hospitalization for chronic obstructive pulmonary disease exacerbation. Lung. 2020;198(3):525–33.
Article
CAS
Google Scholar
Aldibbiat AM, Al-Sharefi A. Do benefits outweigh risks for corticosteroid therapy in acute exacerbation of chronic obstructive pulmonary disease in people with diabetes mellitus? Int J Chron Obstruct Pulmon Dis. 2020;15:567–74.
Article
CAS
Google Scholar
Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–31.
Article
CAS
Google Scholar
Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699–709.
Article
Google Scholar
Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124(2):459–67.
Article
Google Scholar
Walters JA, Tan DJ, White CJ, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;3:CD006897.
PubMed
Google Scholar
Sayiner A, Aytemur ZA, Cirit M, Unsal I. Systemic glucocorticoids in severe exacerbations of COPD. Chest. 2001;119(3):726–30.
Article
CAS
Google Scholar
Chen G, Xie CM, Luo YF. The effects and therapeutic duration of oral corticosteroids in patients with acute exacerbation of chronic obstructive pulmonary diseases. Zhonghua Jie He He Hu Xi Za Zhi. 2008;31(8):577–80.
PubMed
Google Scholar
Ma Z, Zhang W. Short-term versus longer duration of glucocorticoid therapy for exacerbations of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2016;40:84–90.
Article
CAS
Google Scholar
Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic Literature Review Of Systemic Corticosteroid Use For Asthma Management. Am J Respir Crit Care Med. 2020;201(3):276–93.
Article
Google Scholar
Rogers MAM, Lin P, Nallamothu BK, Kim C, Waljee AK. Longitudinal study of short-term corticosteroid use by working-age adults with diabetes mellitus: risks and mitigating factors. J Diabetes. 2018;10(7):546–55.
Article
CAS
Google Scholar
Butler E, Moller MH, Cook O, Granholm A, Penketh J, Rygard SL, et al. The effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in critically ill adults: a systematic review with meta-analysis. Intensive Care Med. 2019;45(11):1540–9.
Article
Google Scholar
Alten R, Nusslein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, et al. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open. 2016;2(1):e000228.
Article
Google Scholar
Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55.
Article
CAS
Google Scholar
Sivapalan P, Jensen JU. Non-eosinophilic severe exacerbations of COPD: what about antibiotics?—authors’ reply. Lancet Respir Med. 2019;7(11):e34.
Article
Google Scholar
Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3):789–91.
Article
Google Scholar
Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019. https://doi.org/10.1016/S2213-2600(19)30176-6.
Article
PubMed
Google Scholar
Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–71.
Article
Google Scholar
Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52(8):2813–23.
Article
Google Scholar
Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, et al. Days alive and out of hospital and the patient journey in patients with heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J. 2011;162(5):900–6.
Article
Google Scholar